Beijing Xinbo Technology Trading Co., Ltd.

For many patients, high medical expenses and medicines have caused financial pain to many families. Due to the pressure that the economy has put on patients and even their families, some people have even worked hard for medical treatment and incurred debts just to save people. Therefore, many patients are intimidated by the disease. In other words, There is no legal basis for treating a disease.
In fact, I don’t need to say more. Many people know that layer upon layer of price increases is the main reason for high drug prices. As a result, the cost of many examinations and the price of drugs are ridiculously expensive.
From the following chain, you can see why drugs are so expensive and examinations cost so much.
The manufacturer's national general agent and provincial agent set the final retail price through centralized bidding and pricing into the hospital (dean, pharmacy department)
Here is a simple example, there is a medicine in a hospital, the winning bidder Price yuan, retail price. The price at the drug store at the door is RMB. The winning bid price is higher than the retail price. Where did the higher portion come from? I can guarantee that there is absolutely no rebate for commonly used low-priced drugs like this. Without rebates, the prices are very high, right? The manufacturer said that the public relations fee is very high. How can it not be added to the price of the drug?
This is a very familiar unspoken rule in the medical industry. As the saying goes, the wool comes from the sheep. If you don’t cheat consumers and patients, who will you cheat?
So here, let me briefly explain why the Indian version of Iressa is a good choice?
According to statistics, Iressa's huge commercial profits are confirmed, and it is also the epitome of the rapid progress of molecular targeted drugs in cancer treatment. In 2017, Iressa’s sales in China were RMB 100 million, and its old rival Tarceva (another targeted drug for lung cancer treatment, produced by Roche Pharmaceuticals) also achieved sales of RMB 100 million. Income.
Foreign-invested drugs in China include two types of patented drugs and original research drugs. In the world, there are only patented drugs and generic drugs, and original drugs are a unique concept in China. They refer to drugs whose patents have expired but are produced by the original patent holder. A reporter from "Daily Economic News" investigated and learned that the prices of these two drugs are very expensive in mainland China.
New drug R&D and innovation takes at least years and costs more than 100 million US dollars. This is a commonly held view in the pharmaceutical industry regarding the time and financial resources required to develop new drugs. After analyzing the number of drug approvals and R&D expenses of large pharmaceutical companies from 2015 to 2018, Forbes magazine concluded that the research and development of new drugs requires at least 100 million U.S. dollars. Among them, AstraZeneca spent an average of 100 million U.S. dollars. R&D expenses top the list.
Let’s take Nexavar as an example. Bayer’s patent for Nexavar in Germany is valid until 2020, but the Indian Patent Office issued a compulsory license to a large Indian pharmaceutical company as early as 2016, allowing them to legally copy Nexavar. Bayer The company filed an infringement lawsuit last year, but was still compulsorily licensed by the Indian authorities on the grounds that the German version was too expensive and ordinary people could not afford it.
There are many pharmaceutical factories in India that have obtained US certification and ship various generic drugs to the world every day. According to statistics, one-fifth of the world's generic drugs are currently produced in India.
For similar reasons, Iressa has also been allowed by Indian policies in India and can be copied. Even the British head office lost the lawsuit when it went to India. This is the Indian state’s protection for generic drugs, allowing the country’s people to afford medicines to treat their illnesses.
Furthermore, due to the advanced technology of Indian generic drugs, it is also very famous in the world.
The reason for the development of India's generic drug technology is that the development of India's generic drug industry is based on the government's relaxation and laissez-faire in patent laws. On the other hand, it may also be related to the Indians' own mentality of only pursuing low prices.